{"id":878116,"date":"2025-08-21T17:37:18","date_gmt":"2025-08-21T21:37:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/"},"modified":"2025-08-21T17:37:18","modified_gmt":"2025-08-21T21:37:18","slug":"quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/","title":{"rendered":"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit<\/b><\/p>\n<p class=\"bwalignc\"><i>Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence<\/i><\/p>\n<p>BILLERICA, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.quanterix.com%2F&amp;esheet=54311448&amp;newsitemid=20250821115585&amp;lan=en-US&amp;anchor=Quanterix+Corporation&amp;index=1&amp;md5=194887b42c6bbfb3a0f2ded36d520297\">Quanterix Corporation<\/a> (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.quanterix.com%2Fproducts-and-services%2Fpharma-services%2F&amp;esheet=54311448&amp;newsitemid=20250821115585&amp;lan=en-US&amp;anchor=Quanterix+Accelerator+Laboratory&amp;index=2&amp;md5=c4d7181901f8b74f5a3894c5b72f575f\">Quanterix Accelerator Laboratory<\/a> a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide.<\/p>\n<p>\n\u201cCollaboration is at the core of the Quanterix Accelerator Laboratory,\u201d said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. \u201cEvery breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.\u201d<\/p>\n<p>\nThe Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa<sup>\u00ae<\/sup> technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology\/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation.<\/p>\n<p>\nThe latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix\u2019s commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation\u2019s largest healthcare markets, New York\u2019s clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards.<\/p>\n<p>\nAccelerator\u2019s Simoa<sup>\u00ae<\/sup> NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu.<\/p>\n<p>\nAdditionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab\u2019s rigor and ultra-sensitive Simoa<sup>\u00ae<\/sup> technology with Lucent Diagnostics\u2019 focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics.<\/p>\n<p>\nTo learn more about the Quanterix Accelerator Laboratory, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.quanterix.com%2Fproducts-and-services%2Fpharma-services%2F&amp;esheet=54311448&amp;newsitemid=20250821115585&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.quanterix.com%2Fproducts-and-services%2Fpharma-services%2F&amp;index=3&amp;md5=04032f4197ac3592798e2678a9e477df\">https:\/\/www.quanterix.com\/products-and-services\/pharma-services\/<\/a>.<\/p>\n<p><b>About Quanterix<br \/>\n<br \/><\/b>Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa<sup>\u00ae<\/sup> technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company<sup>\u00ae<\/sup>, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue\u2014advancing precision medicine from discovery to diagnostics. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.quanterix.com&amp;esheet=54311448&amp;newsitemid=20250821115585&amp;lan=en-US&amp;anchor=www.quanterix.com&amp;index=4&amp;md5=141957ec6b266f7fd9c8be7eae03a602\">www.quanterix.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250821115585\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250821115585\/en\/<\/a><\/span><\/p>\n<p><b>Media Contact<br \/>\n<\/b><br \/>Marissa Klaassen<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@quanterix.com\">media@quanterix.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America New York Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Clinical Trials Health Technology Public Policy\/Government Biotechnology State\/Local Pharmaceutical Health Science Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250821115585\/en\/355264\/3\/Quanterix_Logo_CMYK_Color_viewimage.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass.&#8211;(BUSINESS WIRE)&#8211;Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. \u201cCollaboration is at the core of the Quanterix Accelerator Laboratory,\u201d said Masoud Toloue, PhD, Chief Executive &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-878116","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass.&#8211;(BUSINESS WIRE)&#8211;Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. \u201cCollaboration is at the core of the Quanterix Accelerator Laboratory,\u201d said Masoud Toloue, PhD, Chief Executive &hellip; Continue reading &quot;Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T21:37:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit\",\"datePublished\":\"2025-08-21T21:37:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/\"},\"wordCount\":569,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/\",\"name\":\"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-08-21T21:37:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/","og_locale":"en_US","og_type":"article","og_title":"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit - Market Newsdesk","og_description":"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass.&#8211;(BUSINESS WIRE)&#8211;Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. \u201cCollaboration is at the core of the Quanterix Accelerator Laboratory,\u201d said Masoud Toloue, PhD, Chief Executive &hellip; Continue reading \"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-21T21:37:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit","datePublished":"2025-08-21T21:37:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/"},"wordCount":569,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/","name":"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-08-21T21:37:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250821115585r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-accelerator-laboratory-awarded-rigorous-new-york-state-clinical-laboratory-permit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/878116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=878116"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/878116\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=878116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=878116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=878116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}